A consortium of investors led a $124m Series A and B rounds in Gensciences, a Chineese biopharmaceutical company. The Series A funding came from IDG Capital, New Alliance Capital, and Hygeia Capital, while the series B fundraising was led by Haitong Kaiyuan Investment, along with Efung Capital and Huarong Rongde Asset Management. The fresh capital will be used for the clinical research of biomacromolecular drugs and its commercialization, as well as the construction of a production workshop.